Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 05 Jul 2023 for ImmunoGen, Inc., €12k. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Anna Berkenblit: trading record in brief
Anna Berkenblit (senior executive) discloses dealings in ImmunoGen, Inc. to SEC (Form 4). We count 5 filings; the first trade dates from 30 June 2021 and the latest from 30 June 2023.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The latest filing, published on 5 July 2023, reports a share grant of €12k in ImmunoGen, Inc. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Anna Berkenblit
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
3,264 shares@ US$4.0519.7% of flowCommon StockSEC:0001415889-23-010828:0
436 shares@ US$3.922.6% of flowCommon StockSEC:0001415889-23-000108:0
3,073 shares@ US$3.82518.2% of flowCommon StockSEC:0001415889-22-007332:0
1,761 shares@ US$5.6020.1% of flowCommon StockSEC:0001179110-22-000106:0
2,062 shares@ US$5.5222.2% of flowCommon StockSEC:0001179110-21-007318:0
5 of 5 declarations
